AIC
SPRY icon

AWM Investment Company’s ARS Pharmaceuticals SPRY Stock Holding History

AWM Investment Company’s Portfolio SPRY Stock Details SPRY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-100,000
Closed -$1.02M – 109
2024
Q1 		$1.02M Buy
+100,000
New +$746K 0.13% 89

Other funds holding SPRY

DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
KPF
K2 Principal Fund Toronto, Ontario, Canada $1.43B AUM 29.56% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

AWM Investment Company's SPRY Position: Q2 2024 in Review

AWM Investment Company sold out of ARS Pharmaceuticals (SPRY) in Q2 2024, closing a stake of 100,000 shares — an estimated $1.02M sold.

AWM Investment Company first reported a position in SPRY in Q1 2024 and held it in 1 quarter. The position peaked at $1.02M in Q1 2024. 115 funds tracked by Wall St. Rank hold SPRY as of Q2 2024.

  • AWM Investment Company reported no remaining ARS Pharmaceuticals position as of Q2 2024 after selling out during the quarter.
  • AWM Investment Company sold 100,000 ARS Pharmaceuticals shares in Q2 2024, an estimated $1.02M.
  • AWM Investment Company first reported a position in ARS Pharmaceuticals in Q1 2024 and held it in 1 quarter.
  • AWM Investment Company's ARS Pharmaceuticals position peaked at $1.02M in Q1 2024.
  • 115 funds tracked by Wall St. Rank held ARS Pharmaceuticals as of Q2 2024.

Based on AWM Investment Company's 13F filing for Q2 2024, filed 14 Aug 2024.